The biochemistry of the cell membrane and cellular signalling systems have recently come to the fore as potential targets for the discovery and development of new anticancer drugs (Tritton & Hickman, 1990; Powis, 1991) . As part of this new focus natural products with potentially exploitable biological properties receive increasing attention. The marine animal product bryostatin 1 is a prototype of such agents. The most prominent biochemical feature of this investigational drug is its ability to activate the enzyme protein kinase C (PKC), and this is probably intrinsically linked to its antineoplastic activity. Bryostatin 1 is currently under phase 1 clinical evaluation in the UK, and there is considerable uncertainty as to the potential therapeutic and toxicological implications of PKC modulation. It is especially unclear how pharmacological alteration of the properties of such a crucial and ubiquitous enzyme could be selective, because normal cells, as well as their diseased counterparts, would be susceptible to disruption (Tritton & Hickman, 1990) . In view of this uncertainty and of the prospect of more agents of similar structural and biological complexity entering the oncologist's chemotherapeutic armamentarium it seems appropriate to summarise the scientific basis upon which the potential use of PKC modulators such as bryostatin 1 in cancer treatment is founded. This is the aim of the commentary. In particular recently discovered characteristics of PKC activity and regulation are highlighted as far as they might eventually lead to selective intervention by drugs.
PKC activity
The cellular effects of many growth factors and hormones are brought about by receptor-mediated hydrolysis of the membrane phospholipid phosphatidylinositol 4,5-bisphosphate. This hydrolysis results in the production of inositol 1,4,5-trisphosphate and diacylglycerol. Both molecules function as intracellular second messengers. Inositol 1,4,5-trisphosphate releases Ca2+ from internal stores at the endoplasmic reticulum, and diacylglycerol activates PKC. PKC is an enzyme family with serine/threonine kinase function which regulates many cellular processes, including cell proliferation and differentiation (Nishizuka, 1989) . PKC activity is dependent on the presence of phospholipids, and most PKC isozymes require Ca2" for optimal activity. Most activated PKC is found at the cell membrane, but a fraction has been located associated with the nucleus . Nuclear PKC is possibly of high functional importance as stimulation of PKC elevates, directly or indirectly, the activity of nuclear proto-oncogenes such as c-fos, and c-jun, sometimes referred to as 'immediate early genes'.
The signal transduction pathway which operates via PKC than other types of cancer cells (Hirai et al., 1989) Pharmaceutical Sciences Institute, Aston University, Birmingham appears to be essentially ubiquitous. But the extraordinary diversity of responses to PKC activation could be explained by the multiple gene products that constitute the PKC family (a,jB,ze,A,g, and their tissue-selective distribution (Nishizuka, 1988; Parker et al., 1989; Stabel & Parker, 1991) . Whilst it has not yet been possible to ascribe specific cellular responses to the activation of individual PKC isotypes, investigation of their properties has provided evidence for functional heterogeneity: PKC isozymes differ from each other in substrate specificity and in their dependency on Ca2" Akita et al., 1990) or on diacyglycerol/phospholipid (Ono et al., 1989) for maximal activation.
Is there then a difference between tumours and normal tissues in levels or isozyme content of PKC, which could be therapeutically exploited? The relevant literature is not easy to interpret, which applies also to many other aspects related to PKC. PKC expression has been studied in leukaemias, melanomas, and breast, colon and lung cancers. Subtle but significant differences have been observed. Of the three major PKC isozymes a, P and y, which were found in human leukaemia cells the former two were present in all types of leukaemic cells (Komada et al., 1991) . Acute myelocytic leukaemia cells expressed both types at equal levels, whereas in lymphoid cells expression of PKC-P was more abundant than that of PKC-a. PKC-y was expressed in lymphoid leukaemia, but only sporadically in acute myeloid leukaemia cells. A comparison of murine non-transformed melanocytes and transformed melanoma cells is particularly instructive, as subcellular distribution and overall levels of PKC differed depending on cell type and proliferation state (Brooks et al., 1991) . In quiescent melanocytes most PKC activity was in the cytosol, whereas in the melanoma cells the majority of PKC activity was located in the membrane fraction. Total PKC levels were higher in quiescent melanocytes than in melanoma cells, which in turn contained more enzyme than proliferating melanocytes. These results indicate that overall PKC levels are related to proliferative capacity and that cytosolic enzyme might play an anti-proliferative role. Normal human melanocytes did not express PKC-a, -0, or -'y, whereas the a isozyme was expressed in primary and metastatic melanoma (Becker et al., 1990) . Incongruous with these results Yamanishi et al. (1991) did find PKC-x, -P and -a in primary melanocytes, and they reported that PKC isotype gene expression changed during the progression of melanocytes to metastatic melanoma. PKC levels in surgical specimens of human breast tumours were almost 3-fold the enzyme activities in normal breast tissue obtained from the same patients (O'Brian et al., 1989) . In contrast, in human colonic adenoma or carcinoma samples PKC activity was significantly reduced as compared to adjacent mucosa tissue and mucosa in control subjects (Kopp et al., 1991) . PKC activity in normal colonic mucosa from patients with colorectal cancer was only a third to one half of levels in patients without cancer (Sakanoue et al., 1991) . Human lung carcinoma cells appear to possess higher activities of PKC-x than other types of cancer cells (Hirai et al., 1989) , but PKC-x is also the most abundant isoform of PKC in normal tiusues and cells (Nishizuka, 1989) . Viewed together the data on PKC levels and expression suggest that differences in PKC activity and isotype composition are dependent on origin of tissue and type of malignancy, and that generalisations as to which PKC-isozymes play a role in specific neoplasias cannot be made yet.
PKC activators and growth arrest
In many cells activation of PKC triggers mitogenesis. However in others, mainly malignant cells of human origin, it causes the reverse, cytostatis or cytotoxicity. This observation is germane to the argument that PKC activation might be of therapeutic benefit. Therefore in the following known endogenous and exogenous PKC activators and cell types in which they cause growth arrest are briefly reviewed. Diacylglycerols are the major cellular PKC-activating ligands, certain fatty acids such as arachidonate also have some activatory ability. Upon binding to PKC diacylglycerols increase the affinity of the enzyme for Ca2". Research on PKC gathered momentum when the specific cellular receptor via which tumour promoting phorbol esters exerts its biological effects was shown to be PKC (Nishizuka, 1988) . Phorbol esters, of which 12-O-tetradecanoylphorbol-13-acetate (TPA) (Figure 1 ) is the most potent, are strong activators of PKC. But they are much more resistant to metabolism than diacylglycerols, and it is the protracted stimulation of PKC by phorbol esters which is thought to trigger their effects, including tumour promotion. A fateful but intrinsic consequence of the sustained binding of biochemically stable ligands such as phorbol esters to the enzyme is its eventual demise in that they cause enzyme downregulation (RodriguezPena & Rozengurt, 1984) . Binding to and downregulation of PKC are at the heart of the specificity with which PKC activators exert their effects and both undoubtedly determine differences in efficacy between agents. There are several controversial issues concerning the nature of the binding of activators to PKC and the mechanism proper of activation, and they have recently been cogently reviewed (Blumberg, 1991) . Marked differences in binding affinity of TPA for its receptor sites between the major PKC isozymes (a, P and y) in vitro do not exist. But different phorbol esters do activate PKC isozymes somewhat disparately, consistent with the rigid structural control which governs their biological properties (Hecker, 1985; Brooks et al., 1989) . Six phorbol esters were recently investigated for their proficiency to activate PKC-z, -P, -y, -S, or -e (Ryves et al., 1991) . Four agents were more or less indiscriminate in their effects on the isozymes, but two showed interesting specificity. Sapintoxin A (Figure 1 ) activated all isozymes except PKC-6, whereas 12-deoxyphorbol-13-O-phenylacetate-20-acetate (DOPPA) (Figure 1 ) activated almost exclusively PKC-pl3. Also arachidonate activated PKC-o, -P and --y differentially, depending on specific cofactors (Sekiguchi et al., 1989 ).
Examples of cells in which phorbol esters cause cytostasis or cytotoxicity are MCF-7 breast, A431 epidermal and A549 lung carinoma cells (Gescher, 1985) . Phorbol esters are also growth inhibitors of several transformed melanoma lines in culture, whereas normal melanocytes need the continual presence of phorbol esters in order to grow (Becker et al., 1990; Brooks et al., 1990) HL-60 promyelocytic leukaemia, the phorbol ester-induced loss of proliferative potential is the result of induction of differentiation (Vandenbark & Niedel, 1984) . TPA-induced differentation is often terminal, but in U-973 leukaemia cells it is not, as after removal of phorbol esters cells undergo retrodifferentiation (Hass et al., 1991) . The search for the discovery of nuclear events which trigger differentiation is on, and the TPA-induced 'immediate early' and transient transcription of a HL-60 cell gene has been reported (Shimizu et al., 1991) . It encodes a protein related to products of the jun gene family. One inevitable conclusion of the bewildering literature on the nature and degree of response to PKC activation is that phorbol ester effects are cell-type dependent (Weinstein, 1988) . PKC (Nishikawa et al., 1990) . TPA also activated one of the two major PKC isoforms in HL-60 cells, probably PKC-P, more effectively than the other, PKC-a (Beh et al., 1989) . These results are consistent with the hypothesis that PKC-P is particularly important for induction of differentiation. Accordingly expression of this isozyme, but not of PKC-a, correlated with the responsiveness of KG-1 myeloid leukaemia cells to the differentiating effects of TPA (Hooper et al., 1989) , and 1,25-dihydroxyvitamin D3-induced differentiation of HL-60 cells resulted in an increase of predominantly PKC-P transcripts (Obeid et al., 1990) . Rat embryo fibroblasts and liver epithelial cell lines which were transformed by an activated human c-Ha-ras oncogene displayed a several-fold increase in PKC-a and a concomitant decrease in PKC-c, at both the protein and mRNA levels (Borner et al., 1990) . The authors tendered the intriguing hypothesis that both, upregulation of PKC-a and downregulation of PKC-e, might be necessary for an activated ras gene to accomplish its transforming function, perhaps because PKC-m and PKC-s play reciprocal roles in cell transformation, PKC-ax mediating mitogenic events, whereas PKC-e having the opposite effect. These rat cells are not the only system in which transformation by ras oncogenes causes PKC modulation. Ha-ras or Ki-ras-transformed NIH 3T3 fibroblasts possess constitutively elevated diacylglycerol levels with consequent partial activation and downregulation of PKC (Wolfman & Makara, 1987) , although the isozymes involved have not been identified. The corollary of these findings for therapy might ultimately be that treatment of ras-transformed malignancies should aim at raising PKC-e and/or inhibiting PKC-o activity. In view of the frequency of mutated ras in human malignancies such an approach might lead to broad-spectrum anticancer agents.
There is other evidence which supports the notion that specific PKC activators might be of therapeutic value. Phorbol ester-induced progression of initiated cells to papillomas and carcinomas was prevented by exposing cells to weak promoting regimes using TPA prior to treatment to achieve promotion proper (Reddy & Fialkow, 1990 Weinstein, 1991) . These findings led to the suggestion that in some tumours PKC might act as a growth suppressor gene. It hs to be pointed out though that in many other cell lines overexpression of PKC provokes the enhancement rather than retardation of growth rate (Krauss et al., 1989; Housey et al., 1988; Persons et al., 1988) , which highlights the complex cell-and isozyme-specificity of events catalysed by PKC.
Diacylglycerols have not shown the strong growth-inhibitory properties in the cell lines in which phorbol esters are cytostatic, perhaps due to their swift metabolic removal from the site of action. Dioctanoylglycerol ( Figure 1) was not an efficacious inducer of HL-60 cell differentation (Morin et al., 1987) , nor did it cause cytostasis in MCF-7 (Valette et al., 1987) or A549 cells (Laughton et al., 1989a) unless relatively high cytotoxic concentrations were applied. Synthesis of analogues of diacyglycerols, in which the diester moiety is part of a ring structure to resemble ring C of the TPA molecule, or with an alkylated glycerol backbone, did not yield potent growth-inhibitory agents or compounds with high affinity for PKC (Molleyres & Rando, 1988; Laughton et al., 1989b ).
In the above examples PKC activation is linked with cytostasis more or less directly. Alternatively, PKC activators could conceivably be beneficial in cancer treatment via indirect mechanisms. PKC-mediated alteration of cellular sensitivity to cytotoxic drugs was shown in human ovarian carcinoma (Isonishi et al., 1990) and cervical carcinoma (HeLa) cells (Basu et al., 1990) . Both were rendered more responsive to the antiproliferative effect of cis-diamminedichloroplatinum(II) (cis-DDP) by phorbol esters. Analogues of the non-phorbol ester promoter lyngbyatoxin A had a similar effect (Basu et al., 1991) and the ability of these agents to sensitise cells to cis-DDP was correlated with their ability to activate PKC. These findings invoke the possibility to overcome anticancer drug resistance in certain cells with PKC activators which would restore' sensitivity. However this prospect does not seem to be generally applicable and each cell type may have to be considered separately. In colon cancer cells PKC activation has been shown to be responsible for, or to contribute to, intrinsic drug resistance (Dong et al., 1991) . Multi-drug resistant human KB and mouse sarcoma 180 cells contained significantly higher levels of PKC-x than their drug-sensitive counterparts (Posada et al., 1989) and inhibition of endogenous PKC activity in the insensitive cells did not maintain or increase but decreased resistance to adriamycin. Elevated PKC activity in cells as a cause of decreased rather than increased sensitivity to antitumour cytotoxicants has been explained by PKCmediated activation of gp 170, the product of the multi-drug resistance gene MDR] (Ford & Hait, 1990) . Adriamycinresistant HL-60 cells contained the same level of PKC-a but less PKC-,B than their sensitive counterparts (Aquino et al., 1990 ). Moreover they also possessed PKC-y, which was absent in adriamycin-sensitive HL-60 cells. These results underline the functional importance of specific PKC isoforms in contrast to overall enzyme levels. Regulation of PKC Is specificity possible at the level of PKC regulation? Mechanisms of PKC regulation are complex, but some are amenable to interference by exogenous agents. Exposure of cells to Ca2" or phorbol esters leads to the redistribution of PKC from the cellular cytosol to the particulate subcellular fraction (Kraft & Anderson, 1983) . This association with membranes is presumably normally mediated by diacylglycerol and brings PKC into close proximity with its cofactor phospholipid. Some selectivity was observed in Ca2+-mediated PKC redistribution in rat pituitary cells (Kiley et al., 1990 ). An increase in cytosolic Ca2" caused transcloation of PKC-aand -13 but not of PKC-c. Changes in PKC localisation probably involve its binding to specific 'receptors for activated C-kinase' (RACKs), which were proposed to exist at multiple intracellular sites and the plasma membrane (Mochley-Rosen et al., 1991) . The PKC downregulation observed on sustained exposure to PKC activating ligands is probably due to an increased proteolytic degradation of PKC by endogenous protease (Young et al., 1987; Pontremoli et al., 1990) . Differential kinetics of depletion of PKC isozymes have been reported in several cellular systems (Huang et al., 1989; Ase et al., 1988; Adams & Gullick, 1989) , indicating that the rate at which PKC is downregulated is isoform-and cell type-specific. In rat pituitary cells phorbol ester treatment caused a total loss of immunoreactive PKC-,B and PKC-e, but only partial downregulation of PKC-a (Kiley et al., 1990) , which suggests that prolonged exposure to phorbol esters might be a means to generate a cell population containing mainly PKC-a. To complicate matters downregulation of PKC-c, but not of PKC-P, by TPA in thymocytes depended on elevated levels of Ca2" (Strulovici et al., 1991) . The rate at which PKC recovers after long-term phorbol ester treatment is also isozyme-dependent (Huwiler et al., 1991) . In contrast to the original hypothesis (Kraft & Anderson, 1983) 
Bryostatins
The byrostatins are macrocyclic lactones isolated from marine bryozoans, of which 17 different derivatives have been described (Pettit, 1991) . They activate PKC, in some cells as potently as TPA, in others somewhat less strongly (Berkow & Kraft, 1985; Smith et al., 1985) , and bryostatin 1 was able to displace phorbol esters from their receptors in a semi-purified rat brain PKC preparation at subnanomolar concentrations (De Vries et al., 1988) . A weak structural similarity exists between the bryostatin and phorbol ester molecules as revealed by computer modelling of the spatial arrangement of sets of several oxygen atoms (Wender et al., 1988 (Pettit et al., 1982) , also in M5076 reticulum cell sarcoma, B16 melanoma and LIOA B-cell lymphoma (Hornung et al., 1992) , and in human chronic myelomonocytic leukaemia cells (Lilly et al., 1991) . They have displayed antitumour activity in vivo on multiple i.p. administration in mice with P388 lymphocytic leukaemia, ovarian sarcoma (Pettit et al., 1970) , B16 melanoma (Schuchter et al., 1991) , M5076 sarcoma and LIOA lymphoma (Hornung et al., 1992) .
Significantly, TPA was not cytostatic in the B16 melanoma model. Bryostatins are potent immunomodulators, they activate T-cells, augment neutrophil-and monocyte-mediated cytotoxicity and stimulate bone marrow progenitor cells (Hess et al., 1988; May et al., 1987) . A truly puzzling feature of their biological activity is its paradoxical nature. In many cell lines they are not only agonistic with tumour-promoting phorbol esters but also able to antagonise biochemical responses elicited by themselves or by phorbol esters. They mimic TPA in that they inhibited phorbol ester binding and caused mitogenesis in Swiss 3T3 cells (Smith et al., 1985) , stimulated human polymorphonuclear leukocytes (Berkow & Kraft, 1985) , and induced ornithine decarboxylase, while inhibiting cell-cell communication in keratinocytes (Sako et al., 1987; Pasti et al., 1988) . They also inhibited the growth of A549 cells, albeit only for a period of 24 h, beyond which growth inhibition was slowly reversed (Dale & Gescher, 1989) . Bryostatin 1 failed to induce terminal differentiation of human colon cancer (McBain et al., 1988) and of HL-60 cells (Kraft et al., 1986) . Nevertheless morphological or functional evidence of incomplete differentiation was noticed in most of these lines on exposure to bryostatin. In contrast, bryostatins blocked the differentiation induced by phorbol esters in HL-60 (Kraft et al., 1986) , human colon cancer (McBain et al., 1988) and primary mouse epidermal cells (Sako et al., 1987) . They also restored the differentiation response in Friend erythroleukaemia cells, in which drug-induced differentiation was suppressed by phorbol esters (Dell'Aquila et al., 1987) . Bryostatin 1 blocked both the inhibitory effects on growth elicited by lower concentrations of itself or by TPA (Dale & Gescher, 1989) . Similarly, when combined with TPA bryostatin prevented the TPA-induced inhibition of proliferation of GH4C1 in rat pituitary tumour cells (Mackanos et al., 1991) . Relevant to the prospective use of bryostatin 1 in the clinic is the finding that it lacked tumour-promoting properties in the SENCAR mouse model, indeed it inhibited TPAinduced tumour promotion (Hennings et al., 1987) . The conclusion to be drawn from the perplexing literature on bryostatins is that they exert some of their effects via mechanisms which are independent of those operated by phorbol esters. In none of the above examples was (Warren et al., 1988) . The bryostatin-specific response could also be evoked by concentrations of phorbol dibutyrate which exceeded that necessary to induce differentiation by a factor of 100. This finding underlines the possibility that bryostatins and high concentrations of phorbol esters affect specific PKC isoforms differently from phorbol esters at low concentrations. Bryostatin 1 was less efficient than TPA in competing for specific phorbol ester receptor sites of isolated PKC-P, whereas it equalled TPA in its ability to bind to PKC-a and -' (Kraft et al., 1988) . A significant difference between bryostatins and TPA may be the direction of PKC redistribution. Treatment of HL-60 cells with bryostatin I led to the specific redistribution of activated PKC-Pll, but not of PKC-x to the nuclear envelope, where it triggered the phosphorylation of the polypeptide lamin B (Fields et al., 1988) . In contrast, phorbol dibutyrate caused PKC redistribution towards the plasma membrane (Fields et al., 1988) . Such a discrepancy in PKC relocalisation has yet to be reported for cell lines other than HL-60, in which the bryostatins and phorbol esters possess antagonistic properties. In view of the role of PKC in the mediation of mitogenic signals the concept of inhibiting rather than activating PKC appears to be the more logical strategy in the search for novel avenues in cancer treatment. In support of this idea aberrant expression of PKC has been associated with certain malignancies and metastasis. Transfection of a mutant PKC-x gene into BALB/c 3T3 fibroblasts enhanced their tumourigenicity (Megidish & Mazurek, 1989) , but this finding has subsequently been disputed (Borner et al., 1991) . Metastatic potential has also been correlated with overexpression of normal PKC (Persons et al., 1988; Housey et al., 1988) .
Which are the sites within PKC which could be considered as targets for the design of inhibitors, and which degree of selectivity do they allow? There are firstly the regulatory domain, which contains the activator binding site, secondly the ATP binding site on the catalytic domain, and thirdly the substrate binding domain. A priori the chance of selectivity seems to be lowest in the case of inhibitors of the ATP binding site, as it shows strong homology with other serine and tyrosine kinases. Specificity seems more likely for agents which inhibit predominantly at the regulatory site, and even more possible in the case of inhibitors of the substrate binding site. Examples of agents which inhibit PKC by interaction with the regulatory or catalytic domains are listed in Table I . On the whole their specificity for PKC is moderate. Therefore it is unclear whether their cytostatic potential is mediated via PKC, other kinases or a combination. Important in the context of this discussion is that potent PKC inhibitors do possess growth-inhibitory or cytotoxic properties (Tamaoki & Nakano, 1990) . Thus properties of two representative molecules, staurosporine and sphingosine (Figure 2) , are briefly described in the following. Staurosporine, an indole carbazole, inhibits at the catalytic domain and is one of the most potent PKC inhibitors yet described (Tamaoki et al., 1986) , and sphingolipids are natural constituents of cells and inhibit the regulatory domain . Staurosporine showed an effect on tumour cell invasion and is thus of potential therapeutic interest. At non-toxic concentrations it antagonised the invasion of human bladder carcinoma cells through an artificial basement membrane by inhibiting cell motility (Schwartz et al., 1990) . The drug displayed an unexpected element of specificity in that it affected cell cycle progression and nuclear morphology differently in MOLT-4 human lymphocytic leukaemia cells as compared to normal human lymphocytes (Bruno et al., 1992) . Minor structural modifications have yielded derivatives with greater selectivity for PKC. NBenzoylstaurosporine CGP 41251 (Figure 2 ) is a less potent but more selective PKC inhibitor than staurosporine (Meyer et al., 1989) . Both agents had comparable antitumour activity against a human bladder carcinoma xenograft grown in nude mice. Likewise RO 31-8220 and RO 31-7549 (Figure 2) , cogeners of the staurosporine aglycone, were more specific PKC inhibitors than staurosporine in vitro (Davis et al., 1989) and in intact cells (Dieter & Fitzke, 1991) . UCN-01, hydroxystaurosporine (Figure 2) , is a more selective but weaker and less cytotoxic PKC-inhibitor than staurosporine. But unlike staurosporine, it displayed antineoplastic activity against three human tumour xenografts in nude mice and two murine models, all of which possessed certain aberrations in cellular signal transduction (Akinaga et al., 1991) . As is the case with the bryostatins, staurosporine displays paradoxical effects in that it not only inhibits but also mimics certain phorbol ester effects. Staurosporine enhanced TPAinduced responses in mouse keratinocytes, such as cellular maturation (Dlugosz & Yuspa, 1991) . It was also a weak tumour promoter in the CD-1 mouse model, even though it inhibited promotion induced by phorbol esters (Yoshizawa et al., 1990) . There is an indication that inhibitors of the staurosporine type do not repress all PKC isoforms equally, as a Ca2"-independent PKC isoform from porcine spleen was unaffected by the staurosporine analogue K252a (Gschwendt et al., 1989) .
Lysophingolipids such as sphingosine (Figure 2 ) are metabolites of membrane sphingolipids which may be cellular second messengers . Sphingosine inhibited the TPA-induced differentiation of HL-60 cells (Merrill et al., 1989) , and dihydrosphingosine in the 10-6 M concentration range exerted cytostasis and cytotoxicity against Chinese hamster ovary cells (Stevens et al., 1990) . Both effects were mechanistically attributed to PKC inhibition, which seems to require pH conditions under which the sphingosine amine function is protonated (Bottega et al., 1989) . Unlike sphingosine itself, its synthetic analogues N,Ndimethyl-and N,N,N-trimethyl-sphingosine (Figure 2 ) had moderate antineoplastic activity in vivo against a human gastric carcinoma cell line grown in nude mice (Endo et al., 1991) , and the latter also inhibited the metastatic potential of murine B16 melanoma cells in vivo (Okoshi et al., 1991) . Of the anticancer drugs in clinical use which possess PKCinhibitory properties (Table I) regulatory domain of PKC and inhibit the enzyme at pharmacologically relevant concentrations in the 10-5 M range (O Brian et al., 1985) . PKC inhibition might contribute to its mechanism of antineoplastic action.
The regulatory domain of PKC contains a sequence with a cluster of basic residues, which resembles PKC phosphorylation sites, except that the potential phosphate acceptor serine is replaced by alanine . Binding of this 'pseudosubstrate' to the substrate binding domain is thought to be responsible for the maintenance of inactive PKC in the absence of an activating molecule. A synthetic peptide corresponding to this sequence, Arg-Phe-Ala-Arg-Lys-Gly-AlaLeu-Arg-Gln-Lys-Asn-Val, turned out to be an inhibitor of exquisite specificity for PKC in isolated enzyme preparations and permeabilised cells (Eichholtz et al., 1990) . Manipulations to achieve intracellular delivery of this or similar pseudosubstrates and to restrain their proteolytic destruction might furnish exciting molecules with a better chance of specificity than that displayed by the compounds shown in Table I .
None of the PKC inhibitors so far discovered are particularly selective with respect to PKC isozymes. Nevertheless isozyme-specificity was demonstrated when PKC was irreversibly destroyed by acidic phospholipids in incubates lacking divalent cations Pelosin et al., 1990) . Of the three major PKC isozymes, PKC-y was the most and PKC-a the least susceptible to this inactivating effect. As it seems to depend on rather artificial in vitro conditions it is unlikely to be exploitable in intact cells.
A further example of the complex nature of pharmacological modulation of PKC activity is the activity of the experimental antineoplastic alkyllysophospholipid ET-18-OCH3 (Figure 2 ), a synthetic analogue of 2-lysophosphatidylcholine. ET-18-OCH3 inhibited PKC purified from HL-60 cells with a Ki of 9-1l5M (Zheng et al., 1990) , and the inhibition was competitive with respect to phosphatidylserine. In contrast, the drug activated PKC instead of inhibiting it when the enzyme was prepared from HL-60 cells such that it was still associated with the plasma membrane (Heesbeen et al., 1991) . ET-18-OMe
Conclusions
Because of its pivotal importance for signal transduction mechanisms PKC is undoubtedly a logical target for drug intervention. Subtle differences in terms of levels and heterogeneity of PKC between normal and neoplastic tissues and between different neoplasias are beginning to emerge. These differences might provide selective targets for rational drug design. Among the PKC isozymes the P-form seems to play a crucial role in differentiation, and the design of differentiation inducers should perhaps target PKC-1. In rastransformed malignancies PKC-o might mediate mitogenic and PKC-c anti-mitogenic events. The selective physiological roles of these and other PKC subforms will undoubtedly become clearer soon. Pharmacological alteration of the balance between different PKC isoforms might turn out to be as critical for cell dynamics as modification of a specific PKC isoform. The nature and extent of effects of some of the cytostatic PKC modulators described above are paradoxical and confusing. This might be related to the fact that the functional consequence of PKC modulation seems to be different for each cell type and that the specific roles of PKC isozymes might be cell type-specific. It appears that in order to be of therapeutic value PKC modulators need to be more selective than the currently known agents. Details of the mechanistic link between the growth-inhibitory properties of these agents and the extent of their ability to modulate PKC are still essentially unknown. Bryostatin 1 activates PKC but also antagonises phorbol esters; staurosporine is a potent inhibitor but also exerts phorbol ester-agonistic effects; ET-18-OCH3 is a PKC inhibitor, but under certain conditions an activator. They all mobilise mechanisms yet to be understood in addition to gross PKC modulation. Nevertheless selective pharmacological intervention with PKC-related process might eventually be possible, as isozymes selectivity among PKC activators seems to be no longer an elusive goal. The phorbol esters sapintoxin A and DOPPA are 'lead compounds' in this respect. Inhibitors like staurosporine lack selectivity, but chemical modification has already furnished molecules with increased selectivity for PKC and increased experimental antineoplastic properties compared to the parent molecule. PKC pseudosubstrate analogues might offer even better specificity.
There is no doubt that the complicated interaction between different second messenger signalling systems which involve cascades of kinases, one of which is PKC, will render selective drug action using PKC modulators difficult. Whether it is too complex for therapeutic intervention remains to be seen.
Note added in proof 'In MCF-7 cells, the growth of which is inhibited by TPA but only marginally by bryostatin 1, cytosolic PKC-o was down-regulated by bryostatin 1 without any observable redistribution to the membrane, whereas TPA caused PKC-a redistribution before it was down-regulated (Kennedy et al., 1992) . A cogent model which describes common structural features of PKC activators including the bryostatins has very recently been described (Rando & Kishi, 1992) 
